Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Tawnya C. McKee received her BA from Point Loma College  and her Ph.D. in Medicinal Chemistry with Chris Ireland at the University of Utah. She joined the NCI as a postdoc then became a staff scientist in the Laboratory of Drug Discovery Research and Development (LDDRD). She led a group of natural products chemists working to identify natural products for the treatment of cancer and/or HIV/AIDS. She developed expertise in high throughput assay development amenable to crude NP extracts. In 2013, Tawnya joined the NCI’s Cancer Diagnosis Program (CDP) in the Division of Cancer Treatment and Diagnosis (DCTD). As a Program Director in the Diagnostic Biomarkers and Technology Branch, she manages a grant portfolio focused on biomarkers in GU (includes prostate, kidney, bladder, testicular and penile) and endocrine (thyroid, pituitary) cancers and a variety of technology development initiatives.  She also serves as a lead biomarker reviewer in the Clinical Trial Evaluation Program (CTEP) for biomarker assay utilized in protocols for both early- and late-phase clinical trials. 

Education

  • BA, 1984, Point Loma College
  • PhD, 1990, University of Utah
  • Updated:
Email